Compare VSTS & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | NNNN |
|---|---|---|
| Founded | 1936 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2023 | N/A |
| Metric | VSTS | NNNN |
|---|---|---|
| Price | $11.99 | $25.50 |
| Analyst Decision | Sell | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.88 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 12.0K |
| Earning Date | 05-12-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,734,839,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.98 | $7.03 |
| 52 Week High | $10.38 | $55.65 |
| Indicator | VSTS | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 78.26 | 41.34 |
| Support Level | $7.24 | $19.53 |
| Resistance Level | N/A | $30.21 |
| Average True Range (ATR) | 0.43 | 2.22 |
| MACD | 0.06 | -0.48 |
| Stochastic Oscillator | 86.40 | 20.40 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).